Biblio
Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. Am J Hematol. 2021.
Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine. Am J Hematol. 2021.
Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol Cancer Ther. 2022.
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro. Biochem Pharmacol. 2023:115981.
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023.
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023.
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in Class Rearrangements. JCO Precis Oncol. 2023;7:e2200707.
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res. 2023:OF1-OF18.
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. 2024.